Mimivax.com

Mimivax.com has Server used 198.71.233.15 IP Address with Hostname in United States. Below listing website ranking, Similar Webs, Backlinks. This domain was first 2011-03-13 (10 years, 197 days) and hosted in Scottsdale United States, server ping response time 13 ms

DNS & Emails Contact

This tool is used to extract the DNS and Emails from this domain uses to contact the customer.

Fetching Emails ...

Extract All Emails from Domain

Top Keywords Suggestions

Keywords suggestion tool used Mimivax keyword to suggest some keywords related from this domain. If you want more, you can press button Load more »

1 Minivex
2 Minivac
3 Minivacanta
4 Minivac4chefs
5 Minivac 2
6 Minivac 610
7 Minivac 601
8 Minivac 6010
9 Minivac 8500

Hosting Provider

Website: Mimivax.com
Hostname: ip-198-71-233-15.ip.secureserver.net
Country:
Region: AZ
City: Scottsdale
Postal Code: 85260
Latitude: 33.61190032959
Longitude: -111.89060211182
Area Code: 480
Email AbuseNo Emails Found

Find Other Domains on Any IP/ Domain


New! Domain Extensions Updated .com .org .de .net .uk   » more ...

Domains Actived Recently

   » Revo.com (7 hours ago)

   » Bobbyjonesband.com (1 day ago)

   » Huishoubao.com (12 hours ago)

   » M1file.com (1 day ago)

   » Renhomesantalya.com (13 day ago)

   » Napadrivertours.com (2 day ago)

Results For Websites Listing

Found 47 Websites with content related to this domain, It is result after search with search engine

MimiVax, LLC LinkedIn

Linkedin.com   DA: 16 PA: 20 MOZ Rank: 36

  • MimiVax, LLC | 207 followers on LinkedIn
  • Disrupting Cancer with Immunotherapy | Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient

MimiVax Phase 2 Study Of SurVaxM In Combination With …

Prnewswire.com   DA: 18 PA: 50 MOZ Rank: 69

MimiVax LLC is a NY based private, clinical-stage biotechnology company formed in 2012 to develop and commercialize its lead candidate SurVaxM and pipeline immunotherapeutics for cancer and

MimiVax SurVaxM, Pembrolizumab Study Opens For Recurrent …

Americanpharmaceuticalreview.com   DA: 36 PA: 50 MOZ Rank: 88

  • MimiVax announced a clinical collaboration to assess the combination of SurVaxM and pembrolizumab
  • SurVaxM is a patented peptide immunogen targeting survivin, a cell-survival protein present in glioblastoma and many other cancers
  • This is a Phase 2 study now open at the Cleveland Clinic, Cleveland OH.

SurVaxM Vaccine Appears ‘very Promising’ For Newly Diagnosed …

Healio.com   DA: 14 PA: 50 MOZ Rank: 67

  • SurVaxM (SVN53-67/M57-KLH, MimiVax) is a novel peptide-based vaccine that targets survivin, a tumor-specific antigen nearly universally expressed in patients

MimiVax Phase 2 Study Of SurVaxM In Combination With …

Wfmz.com   DA: 12 PA: 50 MOZ Rank: 66

MimiVax LLC is a NY based private, clinical-stage biotechnology company formed in 2012 to develop and commercialize its lead candidate SurVaxM and pipeline immunotherapeutics for cancer and

Buffalo-based Biotech Startup Inks $148 Million Deal With Chinese …

Bizjournals.com   DA: 19 PA: 50 MOZ Rank: 74

  • MimiVax has completed Phase 1 and Phase 2 clinical trials on a shoestring budget, yielding results which showed their therapy vastly improved the chances of surviving a glioblastoma

MimiVax Phase 2 Study Of SurVaxM In Combination With …

Markets.businessinsider.com   DA: 27 PA: 50 MOZ Rank: 83

About MimiVax LLC MimiVax LLC is a NY based private, clinical-stage biotechnology company formed in 2012 to develop and commercialize its lead candidate SurVaxM and pipeline immunotherapeutics for

SurVaxM Vaccine Therapy And Temozolomide In Treating Patients …

Clinicaltrials.gov   DA: 18 PA: 21 MOZ Rank: 46

  • To evaluate 6-month progression-free survival (PFS6) in patients with survivin positive newly diagnosed glioblastoma multiforme (GBM) treated with at least 4 doses of SVN53-67/M57-keyhole limpet hemocyanin (KLH) peptide vaccine (SurVaxM) and standard of care temozolomide.

Marc Broidy – Marc Broidy – Southern California Entrepreneur And …

Marcbroidy.wordpress.com   DA: 24 PA: 24 MOZ Rank: 56

  • MimiVax is a Buffalo, New York-based biotechnology company with a pipeline of clinical-stage therapeutics for cancer and complex autoimmune diseases
  • On May 30, 2020, the company announced the commencement of a phase 2 study on the safety and tolerability of its lead anti-cancer drug SurVaxM, administered together with pembrolizumab in patients

MimiVax Phase 2 Study Of SurVaxM In Combination With …

Biospace.com   DA: 16 PA: 50 MOZ Rank: 75

  • MimiVax is advised by Varia Ventures, LLC on financing matters and Lippes Mathias Wexler Friedman LLP on legal matters
  • About MimiVax LLC MimiVax LLC is a NY based private, clinical-stage biotechnology company formed in 2012 to develop and commercialize its lead candidate SurVaxM and pipeline immunotherapeutics for cancer and autoimmune diseases.

Fosun Pharma, MimiVax To Jointly Develop And Commercialize …

News-medical.net   DA: 20 PA: 50 MOZ Rank: 80

SurVaxM, which MimiVax is developing based on technology licensed from Roswell Park, is an immunotherapy designed to stimulate the immune system to kill tumor cells that contain survivin, a

Roswell Doctors Develop New Medicine That Could Ease Treatment …

Wivb.com   DA: 12 PA: 50 MOZ Rank: 73

  • “It works similar to how you think a flu vaccine works,” said Michael Ciesielski, Chief executive officer of MimiVax
  • MimiVax is a Roswell Park spinoff company spearheading the clinical trial.

Buffalo-based Biotech Startup Inks Deal With Chinese Pharma Giant …

Wgrz.com   DA: 12 PA: 50 MOZ Rank: 74

  • MimiVax has long presented an exciting opportunity to develop a cutting-edge cancer therapy in Buffalo
  • Now the spinout from Roswell Park Comprehensive Cancer Center is a lot

Vaccine For Glioblastoma Awarded Orphan Drug Status By FDA

Ajmc.com   DA: 12 PA: 50 MOZ Rank: 75

  • MimiVax announced that its immunotherapy vaccine SurVaxM, which is being tested in clinical trials for glioblastoma, has been designated an orphan drug by the FDA

Roswell Leads Investment Into Buffalo-based Biotech Co., …

Bizjournals.com   DA: 19 PA: 50 MOZ Rank: 83

MimiVax is one of the most promising biotech efforts in Buffalo, having already completed phase 1 and 2 clinical trials that showed its SurVaxM vaccine vastly improved patients’ chances of

Chinese Drug Company Helps Fuel Promising Roswell Park Brain …

Buffalonews.com   DA: 15 PA: 50 MOZ Rank: 80

  • Fosun Pharma agreed to pay $10 million upfront so MimiVax can conduct phase II clinical trials to further gauge the effectiveness of the immunotherapy drug
  • The company also is eligible to receive

MimiVax LLC And Shanghai Fosun Pharmaceutical Industrial …

Prnewswire.com   DA: 18 PA: 50 MOZ Rank: 84

MimiVax LLC is a NY based private, clinical-stage biotechnology company formed in 2012 to develop and commercialize its lead candidate SurVaxM and pipeline immunotherapeutics for cancer and

MimiVax Phase 2 Study Of SurVaxM In Combination With …

Pipelinereview.com   DA: 18 PA: 50 MOZ Rank: 85

  • MimiVax is advised by Varia Ventures, LLC on financing matters and Lippes Mathias Wexler Friedman LLP on legal matters
  • About MimiVax LLC MimiVax LLC is a NY based private, clinical-stage biotechnology company formed in 2012 to develop and commercialize its lead candidate SurVaxM and pipeline immunotherapeutics for cancer and autoimmune diseases.

Lawyer Scott Friedman Helps Shepherd Medical Breakthroughs To …

Buffalonews.com   DA: 15 PA: 50 MOZ Rank: 83

  • Mike and Robert patented a cancer vaccine and I helped the two of them form a company called Mimivax LLC that licensed the vaccine out of Roswell Park
  • Their cancer vaccine is now being used in a

MimiVax LLC And Shanghai Fosun Pharmaceutical Industrial …

Markets.businessinsider.com   DA: 27 PA: 50 MOZ Rank: 96

"MimiVax is committed to disrupting cancer through the development of highly innovative immunotherapeutics aimed at increasing patient survival rates, so we are very excited to be working with

Michael Ciesielski

Linkedin.com   DA: 16 PA: 16 MOZ Rank: 52

  • At MimiVax, our mission is to disrupt cancer
  • To increase survival and send hope through the development of highly innovative immunotherapies aimed at improving patient's lives.

Roswell Park Spinoff Company Advances Toward New Clinical Trial …

Newswise.com   DA: 16 PA: 50 MOZ Rank: 87

MimiVax LLC is a NY based private, clinical-stage biotechnology company formed in 2012 to develop and commercialize its lead candidate SurVaxM and pipeline immunotherapeutics for cancer and

Protein-targeting Vaccine Extends Survival In Glioblastoma

Healio.com   DA: 14 PA: 50 MOZ Rank: 86

  • SurVaxM (MimiVax) is a peptide vaccine that targets survivin
  • Phase 1 study results have shown the vaccine to be safe for patients with malignant gliomas.

Roswell Park Team Working On Cure For Brain Cancer

Wkbw.com   DA: 12 PA: 50 MOZ Rank: 85

  • A research team from Roswell Park Comprehensive Cancer Center, Mimivax LLC and Cleveland Clinic is working on a clinical trial for glioblastoma patients

Sending Hope To Cancer Patients Niagara University

Niagara.edu   DA: 15 PA: 33 MOZ Rank: 72

  • In 2012, they launched MimiVax to license this technology and take it from the lab into clinical trials
  • “At some point, you realize curing cancer cells in the laboratory only takes you so far,” Dr
  • “You look at (the technology) and work to realize its potential to be …

A Vial Of Hope: Cancer Drug Developed At Roswell Headed For Big …

Wgrz.com   DA: 12 PA: 50 MOZ Rank: 87

  • — A drug developed at Roswell Park Comprehensive Cancer Center is headed for a big clinical trial in the U.S
  • A Roswell spin-off company, Mimivax, has signed a

Oncolytic Viruses On The Rise

Deep-dive.pharmaphorum.com   DA: 26 PA: 50 MOZ Rank: 24

  • MimiVax is a biotech that span out of Roswell Park Comprehensive Cancer Center
  • The company’s lead product is SurVaxM, a peptide-based vaccine that has shown promise in brain cancer in phase II trials
  • Standard therapy for glioblastoma is surgery followed by chemoradiation and then adjuvant chemotherapy, which produces a median overall

Week In Review: Fosun Pharma Acquires Brain Cancer …

Seekingalpha.com   DA: 16 PA: 50 MOZ Rank: 93

  • Shanghai Fosun Pharma (SHA:600196) (HK:2196) announced a $148 million agreement to acquire China rights to SurVaxM, a novel immunotherapy aimed at glioblastoma, from MimiVax

Study Of Pembrolizumab Plus SurVaxM For Glioblastoma At First …

Clinicaltrials.gov   DA: 22 PA: 21 MOZ Rank: 71

  • The safety and scientific validity of this study is the responsibility of the study sponsor and investigators
  • Listing a study does not mean it has been evaluated by the U.S

MimiVax To Present Results Of SurVaxM Immunotherapy In …

Biospace.com   DA: 16 PA: 50 MOZ Rank: 95

  • MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic targeted therapies for cancer
  • Our proprietary portfolio is based on technology licensed from Roswell Park Comprehensive Cancer Center.

4 Glioblastoma Clinical Trials To Watch – Consult QD

Consultqd.clevelandclinic.org   DA: 29 PA: 41 MOZ Rank: 100

  • Ahluwalia disclosed the following commercial relationships relevant to the studies profiled above: consulting fees and contracted research from AbbVie, and contracted research and stock options with MimiVax.

Proteasome Inhibitors Market Compound Annual Growth Rate …

Marketwatch.com   DA: 19 PA: 50 MOZ Rank: 100

  • Market Players Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales

Corticosteroids

My.clevelandclinic.org   DA: 22 PA: 34 MOZ Rank: 88

  • Commonly referred to as steroids, corticosteroids are a type of anti-inflammatory drug
  • They are typically used to treat rheumatologic diseases, like rheumatoid arthritis, lupus or vasculitis (inflammation of the blood vessels)
  • Specific corticosteroids include the medications cortisone and …

Global And China Proteasome Inhibitors Market Insights, Forecast …

Reportsnreports.com   DA: 23 PA: 50 MOZ Rank: 17

  • MimiVAx Corporation Information Table 104
  • MimiVAx Description and Business Overview Table 105
  • MimiVAx Proteasome Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 106
  • MimiVAx Recent Development Table 108
  • TG Therapeutics Corporation Information Table 109.

Phase II Trial Evaluates Safety Of Pembrolizumab Plus SurVaxM In …

Consultqd.clevelandclinic.org   DA: 29 PA: 50 MOZ Rank: 16

  • Phase II Trial Evaluates Safety of Pembrolizumab plus SurVaxM in Recurrent Glioblastoma
  • Cleveland Clinic researchers are testing a novel immunotherapy/cancer vaccine combination in patients with recurrent glioblastoma, in hopes of finding an effective treatment for a condition with poor survival outcomes and a shortage of viable therapeutic options.

SurvaxM May Prolong Survival In Glioblastoma

News.cancerconnect.com   DA: 22 PA: 50 MOZ Rank: 15

Collaborators from organizations including Roswell Park Comprehensive Cancer Center, the Cleveland Clinic and MimiVax LLC will shared data from their phase II study of SurVaxM as part of a combination treatment for patients with glioblastoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Global Proteasome Inhibitors Market Size 2021 Top Manufacturers …

Marketwatch.com   DA: 19 PA: 50 MOZ Rank: 14

  • Johnson and Johnson Takeda Pharmaceutical Millennium Pharmaceuticals MimiVAx TG Therapeutics
  • To Understand How Covid-19 Impact Is Covered in This Report - https:

Proteasome Inhibitors Market Technology, Recent Trends, Future …

Manometcurrent.com   DA: 18 PA: 50 MOZ Rank: 13

  • Top Key Players Included in This Report: Johnson & Johnson, Takeda Pharmaceutical, Millennium Pharmaceuticals, MimiVAx, and TG Therapeutics
  • The study will include an analysis of the major market competitors as well as data on recent mergers and acquisitions in the global Proteasome Inhibitors market and its subsegments.

Fosun Pharma, MimiVax Commun Pour Développer Et …

News-medical.net   DA: 20 PA: 32 MOZ Rank: 90

  • MimiVax est éligible pour recevoir des $28 millions complémentaire dans les étapes du développement et $110 millions dans des étapes de ventes
  • SurVaxM, que MimiVax développe a basé sur la

Effect Of Nivolumab Vs Bevacizumab In Patients With Recurrent …

Jamanetwork.com   DA: 15 PA: 42 MOZ Rank: 96

This randomized clinical trial examines the effect of programmed cell death 1 immune checkpoint inhibition with nivolumab on overall survival for patients with recurrent glioblastoma.

EU Multiple Myeloma Market Analysis Size, Share, Trends Forecast …

Manometcurrent.com   DA: 18 PA: 50 MOZ Rank: 10

  • The following research on the EU Multiple Myeloma Market Analysis market cast lights on the market key driver, market size, competitors, major market segments, and current trends in the respective market
  • This research also fetches up the recent data over the Research & Developments which act as a major driving parameter in the forecasted Period 2019-2028.

Immune Checkpoint Inhibitors In Brain Metastases: From Biology …

Ascopubs.org   DA: 12 PA: 24 MOZ Rank: 77

  • Cancer immunotherapy has been a subject of intense research over the last several years, leading to new approaches for modulation of the immune system to treat malignancies
  • Immune checkpoint inhibitors (anti–CLTA-4 antibodies and anti–PD-1/PD-L1 antibodies) potentiate the host’s own antitumor immune response
  • These immune checkpoint inhibitors have shown impressive clinical efficacy in

Recently Analyzed Sites

Revo.com (7 hours ago)

Bobbyjonesband.com (1 day ago)

Huishoubao.com (12 hours ago)

M1file.com (1 day ago)

Renhomesantalya.com (13 day ago)

Trekksoft.com (6 hours ago)

Tibbo.com (4 day ago)

Myauburnmeadows.com (10 seconds ago)

Tailspinbandsc.com (2 day ago)

Dungscanada.com (4 day ago)

Jfsorange.org (2 day ago)

Marloweslu.com (6 day ago)